Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection
NCT06734260Phase 3Recruiting
- Sponsor
- Eighth Affiliated Hospital of Sun Yat-sen University
- Start
- Sep 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of keverprazan in Helicobacter pylori infection, sponsored by Eighth Affiliated Hospital of Sun Yat-sen University. Started Sep 2024; status: recruiting.
02
Drugs
keverprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06734260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06734260.